Inflation And COVID Put Pressure On Europe’s Paracetamol Supply Chain
Inflation, new COVID-19 waves and delayed cold and flu outbreaks are causing disruption to Europe's paracetamol supply chain. Industry is not currently concerned, but regulators, for example in France, are introducing measures to prevent this issue spreading from children's to adult forms of the drug, as well as to ibuprofen-based alternatives.
You may also be interested in...
The majority of European consumers use dietary supplements and do so responsibly, a recent survey by industry association Food Supplements Europe shows. Reflecting a common concern for well-being and immunity, vitamin D is the most popular supplement ingredient, followed by vitamin C and magnesium.
European consumers are increasingly turning towards self-care options, research by Stada Arzneimittel shows. Especially in the areas of stress, sleep and mental health, they are seeking out alternatives to conventional medicine, such as dietary supplements, and support from new health technologies, like digital health apps.
In this episode, HBW Insight talks to regulatory expert Mihai Inceu about the challenges of innovating in Europe’s thriving food supplements market. Senior regulatory affairs officer at consultancy firm Jensen R+, Inceu highlights some of the issues companies face in putting new wellness products onto the European market, particularly if they want to make health claims for herbal ingredients, also known as botanicals. As well as giving good advice about how to avoid getting into trouble with regulators, Inceu also points to some of the latest trends in this dynamic consumer health space.